Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,459 signal articles · 145 in last 24h · 154,156 total before filter · latest 1h ago
145last 24h
874last 7d
145● bullish (7d)
96● bearish (7d)
214publishers
AllMacro211Earnings107M&A125Regulatory21Product21Analyst17
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
KKR Hit With $250 Million Penalty Over Antitrust Violations
Benzinga Private Markets28d agoneutral
KKR Hit With $250 Million Penalty Over Antitrust Violations

KKR & Co. (NYSE:KKR) is set to pay a $250 million civil penalty after the private equity firm allegedly violated the Hart-Cottrell-Rodino Act by withholding and altering documents and failing to make required filings. The HSR Act requires M&A parties...

China launches year-long auto quality drive, mandates defect recalls
Reuters28d agobearish
China launches year-long auto quality drive, mandates defect recalls

BEIJING, Aug 27 () - Chinese regulators on Thursday ordered automakers to file proactive recall plans for any defects uncovered in self-audits, ‌as part of a year-long campaign to improve vehicle quality ‌and safety in the world's largest auto market. Tesla and eight Chinese electric vehicle makers ​on August 21 announced fixes affecting a combined 4.

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
Benzinga29d agoneutral
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

What Is Intuit (INTU) Facing In This New Investor Lawsuit?
Simply Wall St.31d agobearish
What Is Intuit (INTU) Facing In This New Investor Lawsuit?

Intuit (NasdaqGS: INTU) and several top executives face a new class action lawsuit alleging they misled investors about generative AI competition and Mailchimp performance. The complaint claims Intuit understated the competitive threat from generative AI tools and misrepresented trends in Mailchimp's business. Plaintiffs have expanded the suit to cover a longer class period, building on earlier litigation focused on similar issues. The case raises fresh questions about Intuit's disclosures...